Effect of Catheter Ablation Vs Medical Therapy on Quality of Life among Patients with Atrial Fibrillation: the CABANA Randomized Clinical Trial
Daniel B. Mark,Kevin J. Anstrom,Shubin Sheng,Jonathan P. Piccini,Khaula N. Baloch,Kristi H. Monahan,Melanie R. Daniels,Tristram D. Bahnson,Jeanne E. Poole,Yves Rosenberg,Kerry L. Lee,Douglas L. Packer,Richard A. Robb,Maryam E. Rettmann,Beth Martinez,Alice Mascette,Neal Jeffries,L. Brent Mitchell,Greg G. Flaker,Hussein R. Al-Khalidi,Adam Silverstein,Alicia Ellis,Sheri A. Ussery,Kathleen L. Moretz,Sarah Hagen,Kevin Anstrom,Khaula Baloch,Diane M. Liu,Janet Blount,Patricia Cowper,David Knight,Elizabeth F. O'Neal,David R. Holmes,Jerome Breen,David Wilber,James Reiffel,Peter Kowey,Gerald Naccarelli,John P. DiMarco,D. Wyn Davies,Riccardo Cappato,Jon M. Kalman,Karl-Heinz Kuck,Gerhardt Hindricks,Hugh Calkins,William G. Stevenson,Alfred Buxton,Anne B. Curtis,Barry R. Davis,Connie M. Ulrich,Ralph Lazzara,Terry Peters,Jared T. Bunch,James Daubert,Blair Halperin,John Holshouser,Steven Kutalek,Greg Michaud,Paul Mounsey,George Wyse,Greg Flaker,Rodney Bell,Amold Greenspon,William Logan,Pradeep Sahota,Niranjan Singh,Richard Schilling,Atul Verma,Tristram Bahnson,Brian DeVille,Kristi Monahan,John DiMarco,Mario Gonzalez,Jeanne Poole,Kris Patton,Jordan Prutkin,George Johnson,Nazem Akoum,Pierre Auokar,Joseph Blatt,Birgersdotter-Green Ulrika (Riki),Yong-Mei Cha,Siva Mulpuru,Peter Noseworthy,Mina Chung,Marye Gleva,Taya Glotzer,Charles Henrikson,Eric Stecker,Yousuf Kanjwal,Jack Kron,Vikas Kuriachan,Owen Obel,Ravi Ranjan,Robert Rho,Andrea Russo,Renee Sullivan,Wendy Tzou,Sarina van der Zee,Laura Vitali Serdoz,Mauri Wilson,Wayne Bowen,Evgeny Pokushalov,Alexander Romanov,E. Meshalkin,T. Jared Bunch,Georg Noelker,Douglas Packer,Gerhard Hindricks,Andrey Ardashev,Amiran Revishvili,George Matsonashvili,Pugazhendhi Vijayaraman,Huseyin Ince,Christopher Piorkowski,Thomas Neumann,George Veenhuyzen,Anil Gehi,Felix Sogade,Carlo Pappone,Adam Berman,Alaa Shalaby,Venkat Tholakanahalli,Eugen Palma,Nitish Badhwar,Haroon Rashid,Craig Cameron,John Hummel,Pablo Saavedra,Brian Deville,Julian Chun,Javier Roman-Gonzalez,Stephen Willems,Hasan Garan,Eric Michael Crespo,Peter Cheung,Gerian Groenefeld,Claudio Schuger,Tariq Salam,Yanzong Yang,Dan Wichterle,Johannes Brachmann,Josef Kautzner,John Jayachandran,Young-Hoon Kim,Christopher Cole,Bengt Herweg,Martin Lowe,Anne Dougherty,Sergey Popov,Stefan Spitzer,Robert Bernstein,Jay Simonson,Eric Buch,Shulin Wu,Mohammed Khan,Timothy Shinn,Petr Neuzil,James Mangrum,Moussa Mansour,Markus Zabel,Jonathan Kalman,Jose Sanchez,Steven Rothman,Anil Bhandari,Cynthia Tracy,Raul Mitrani,Vicken Vorperian,Derek Connelly,Darryl Wells,Chang-Sheng Ma,S. Luke Kusmirek,Melissa Robinson,Donald Rubenstein,Emilio Vanoli,Shu Zhang,Jennifer Cummings,Mohan Viswanathan,George Monir,Francis Marchlinski,Jay Franklin,Bruce Koplan,Prashanthan Sanders,Eric Rashba,Mark Gallagher,Bernd Gonska,Minglong Chen,Peter Leong-Sit,John Zimmerman,Nayer Pezeshkian,Andrew Cohen,Saulius Kalvaitis,David Davies,Martin Borggrefe,Hui-Nam Pak,Gerald Greer,James Coromilas,Farhat Khairallah,Guillermo Sosa-Suarez,Bruce Lindsay,Westby Fisher,Steven Bailin,Andy Tran,Zdenek Starek,Mark Preminger,Robert Sheppard,Alexandru Costea,Kenneth Ellenbogen,Thomas Arentz,Roberto De Ponti,Ryan Aleong,Byron Colley,Khawaja Baig,Kousik Krishnan,Syamkumar Divakara Menon,Tony Simmons,Gregory Bruce,Larry Chinitz,Andrea Natale
DOI: https://doi.org/10.1001/jama.2019.0692
IF: 11.816
2019-01-01
JAMA
Abstract:IMPORTANCE Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain. OBJECTIVE To determine whether catheter ablation is more beneficial than conventional drug therapy for improving QOL in patients with AF. DESIGN, SETTING, AND PARTICIPANTS An open-label randomized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic patients with AF older than 65 years or 65 years or younger with at least 1 risk factor for stroke. Patients were enrolled from November 2009 to April 2016 from 126 centers in 10 countries. Follow-up ended in December 2017. INTERVENTIONS Pulmonary vein isolation, with additional ablation procedures at the discretion of the investigators, for the catheter ablation group (n = 1108) and standard rhythm and/or rate-control drugs selected and managed by investigators for the drug therapy group (n = 1096). MAIN OUTCOMES AND MEASURES Prespecified co-primary QOL end points at 12 months, including the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary score (range, 0-100; 0 indicates complete disability and 100 indicates no disability; patient-level clinically important difference, >= 5 points) and the Mayo AF-Specific Symptom Inventory (MAFSI) frequency score (range, 0-40; 0 indicates no symptoms and 40 indicates the most severe symptoms; patient-level clinically important difference, <=-1.6 points) and severity score (range, 0-30; 0 indicates no symptoms and 30 indicates the most severe symptoms; patient-level clinically important difference, <=-1.3 points). RESULTS Among 2204 randomized patients (median age, 68 years; 1385 patients [63%] were men, 946 [43%] had paroxysmal AF, and 1256 [57%] had persistent AF), the median follow-up was 48.5 months, and 1968 (89%) completed the trial. The mean AFEQT summary score was more favorable in the catheter ablation group than the drug therapy group at 12 months (86.4 points vs 80.9 points) (adjusted difference, 5.3 points [95% CI, 3.7-6.9]; P <.001). The mean MAFSI frequency score was more favorable for the catheter ablation group than the drug therapy group at 12 months (6.4 points vs 8.1 points) (adjusted difference, -1.7 points [95% CI, -2.3 to -1.2]; P <.001) and the mean MAFSI severity score was more favorable for the catheter ablation group than the drug therapy group at 12 months (5.0 points vs 6.5 points) (adjusted difference, -1.5 points [95% CI, -2.0 to -1.1]; P <.001). CONCLUSIONS AND RELEVANCE Among patients with symptomatic atrial fibrillation, catheter ablation, compared with medical therapy, led to clinically important and significant improvements in quality of life at 12 months. These findings can help guide decisions regarding management of atrial fibrillation.